A Phase 1 interventional study of MK-2060 and Placebo in Venous Thrombosis, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 246 studies in Venous Thrombosis with a site in United States — 23 open to participants now, 31 under way, 5 of them phase 3. Venous Thrombosis · United States.
Among the 246 studies in Venous Thrombosis with a site in United States, this one is the 152nd largest by enrollment of the 184 interventional ones that give a count, is one of 5 that started in 2024, is one of 15 in phase 1, and was the 228th registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →23 of the 246 studies in Venous Thrombosis with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Bulgaria, Japan and 2 more countries
Ages 18+
W.L.Gore & Associates · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Georgia, Japan
Ages 18+
Argon Medical Devices · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States, Australia
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
246 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 31 · Phase 3 45 · Phase 4 22
First in 1999; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 130 across the 184 interventional studies, 221 across the 60 observational. Of the 193 that completed or were terminated, 92 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 246 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 1 study filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
13 of the studies in Venous Thrombosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04924322Phase 3Yale UniversityCatheter-Related Early Thromboprophylaxis With Enoxaparin Studies | 2027-04-30 |
| NCT07213778Phase 3Regeneron PharmaceuticalsREGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants | 2027-05-17 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT06519435Mayo ClinicNon-invasive Venous Air Plethysmography Assessment of Venous Hemodynamics in Patients Suspected Deep Venous Obstruction Used in Conjunction With Intermittent Pneumatic Compression. | 2026-12 |
| NCT06451003Medical University of South CarolinaIntervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 246 studies in Venous Thrombosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of MK-2060 via intravenous (IV) infusion over 20 minutes on Day 1.
Biological: MK-2060
Participants will receive a single dose of MK-2060 via IV infusion over 10 minutes on Day 1.
Biological: MK-2060
Participants will receive a single dose of MK-2060 via syringe over 5 minutes on Day 1.
Biological: MK-2060
Participants will receive a single dose of MK-2060 via syringe over 2.5 minutes on Day 1.
Biological: MK-2060
Participants will receive a single dose of MK-2060 via syringe over 1 minute on Day 1.
Biological: MK-2060
Participants will receive a single dose of saline via IV infusion or syringe over MK-2060-matched time period on Day 1.
Biological: Placebo
Single doses of MK-2060 will be administered via IV infusion or syringe on Day 1 according to randomization.
Single doses of placebo will be administered via IV infusion or syringe on Day 1 according to randomization.
Number of Participants With An Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants that experience an AE will be reported.
Time frame: Up to 134 days
Number of Participants Discontinuing the Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants that discontinue the study due to an AE will be reported.
Time frame: Up to 134 days
Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to Infinity (AUC0-inf)
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess AUC0-inf.
Time frame: Predose and at designated time points post dose up to 120 days
Maximum Observed Plasma Concentration (Cmax) of MK-2060
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess Cmax.
Time frame: Predose and at designated time points post dose up to 120 days
Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours (AUC0-168)
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess AUC0-168 hours.
Time frame: Predose and at designated time points post dose up to 120 days
Plasma Concentration of MK-2060 at 168 Hours (C168)
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess C168 hours.
Time frame: Predose and at designated time points post dose up to 120 days
Time to Maximum Observed Plasma Drug Concentration (Tmax) of MK-2060
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess Tmax.
Time frame: Predose and at designated time points post dose up to 120 days
Plasma Elimination Terminal Half-life (t ½) of MK-2060
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess t½ .
Time frame: Predose and at designated time points post dose up to 120 days
Apparent Oral Clearance (CL/F) of MK-2060
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess CL/F.
Time frame: Predose and at designated time points post dose up to 120 days
Plasma Apparent Volume of Distribution (Vz/F) of MK-2060
Plasma samples will be collected at pre-specified time points pre- and post-dose to assess Vz/F.
Time frame: Predose and at designated time points post dose up to 120 days
Fold Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060
Plasma samples will be collected at baseline and pre-specified time points post-dose to assess aPTT values. The fold change from baseline will be reported.
Time frame: Baseline and up to 120 days
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Oct 2024 to primary completion in Apr 2025, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-2060